阿托伐他汀对2型糖尿病患者内皮细胞微粒和颈动脉内膜中膜厚度的影响
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:


The Effects of Atorvastatin on the Level of Endothelial Microparticles and Carotid Intima Media Thickness in Type 2 Diabetes Mellitus
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的 观察阿托伐他汀对2型糖尿病患者内皮细胞微粒水平及颈动脉内膜中膜厚度(IMT)的影响。方法 选取2型糖尿病住院患者90例,年龄45~75岁,随机分为阿托伐他汀组和辛伐他汀组。所有患者均在生活方式干预的同时给予口服降糖药和(或)胰岛素治疗,肠溶阿司匹林0.1 g qd,阿托伐他汀组每晚加服阿托伐他汀片20 mg,辛伐他汀组每晚加服辛伐他汀片20 mg,总疗程24周,观察治疗前后内皮细胞微粒、低密度脂蛋白胆固醇(LDLC)及颈动脉IMT的变化,并分析它们之间的相关性。结果 与治疗前相比,阿托伐他汀组和辛伐他汀组IMT、内皮细胞微粒及LDLC水平均明显下降(P<0.05),阿托伐他汀降低IMT、内皮细胞微粒及LDLC的作用强于辛伐他汀(P<0.05),两组降低幅度差异有统计学意义(P<0.05),治疗前后两组内皮细胞微粒及LDLC的变化值与IMT的变化值呈正相关关系(P<0.05)。结论 他汀类药物能够降低2型糖尿病患者颈动脉IMT、内皮细胞微粒及LDLC水平,其抗动脉粥样硬化作用除与降脂作用有关外,可能还与抑制内皮细胞微粒释放有关。阿托伐他汀不仅在降低LDLC上优于辛伐他汀,而且在降低内皮细胞微粒上同样优于辛伐他汀,由此推测阿托伐他汀的抗动脉粥样硬化作用强于辛伐他汀可能与此相关。

    Abstract:

    Aim To investigate the effects of atorvastatin on the level of endothelial microparticles (EMP) and carotid artery intima-media thickness (IMT) in type 2 diabetes mellitus (T2DM) patients. Methods To select 90 cases of type 2 diabetes mellitus resident patients,aged between 45 and 75 years old,who were randomly classified into the atorvastatin group and simvastatin group. Under the circumstance of the intervention of life style,all patients undertook oral antidiabetic drug and/or insulin therapy simultaneously,and with aspirin 0.1 g qd. Atorvastatin group was given atorvastatin 20 mg more every night,simvastatin group was given simvastatin 20 mg more every night. The entire course of treatment lasted 24 weeks. The level of EMP,low density lipoprotein cholester (LDLC),IMT was detected before and after the treatment,and the correlation between them was analyzed statistically. Results In the atorvastatin group and simvastatin group,the IMT decreased significantly (P<0.05) after therapy,while the plasma concentration of EMP,LDLC were decreased (P<0.05),and the ability of atorvastatin lowering IMT,EMP and LDLC was stronger than the effect of simvastatin. There was positive relationship existing in the values of EMP,LDLC and IMT between the two groups before and after the therapy(P<0.05). Conclusion Statins was capable of reducing the IMT,LDLC and EMP in patients with T2DM. Its anti-atherogenic ability was not only associated with the lipid-lowering effect,but also might be related to the inhibition of EMP release. Atorvastatin was superior compared with simvastatin on reducing both LDLC and EMP,which might account for the phenomenon of the stronger atherosclerosis resistant of atorvastatin compared with simvastatin.

    参考文献
    相似文献
    引证文献
引用本文

马鸿伟,任卫东,张 斌,王俊明,刘宏强,胡利梅,谷 君,张秋子.阿托伐他汀对2型糖尿病患者内皮细胞微粒和颈动脉内膜中膜厚度的影响[J].中国动脉硬化杂志,2015,23(08):829~833.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2014-09-01
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2015-07-21